BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.
作者信息
Dirican Ebubekir
机构信息
Istanbul Aydın University, Vocational School of Health Services, Istanbul, Turkey.
Marmara University, School of Medicine Department of Medical Biology, Istanbul, Turkey.
出版信息
Asian Pac J Cancer Prev. 2020 Jan 1;21(1):1. doi: 10.31557/APJCP.2020.21.1.1.
Abstract
摘要
相似文献
1
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.
Asian Pac J Cancer Prev. 2020 Jan 1;21(1):1. doi: 10.31557/APJCP.2020.21.1.1.
2
Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.
J Clin Pathol. 2019 Mar;72(3):263-264. doi: 10.1136/jclinpath-2018-205483. Epub 2018 Oct 25.
3
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5.
4
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
J Transl Med. 2016 Oct 13;14(1):292. doi: 10.1186/s12967-016-1053-z.
5
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6.
6
Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
BMC Cancer. 2016 Jul 12;16:454. doi: 10.1186/s12885-016-2493-9.
7
Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Dis Markers. 2018 Jun 19;2018:2959801. doi: 10.1155/2018/2959801. eCollection 2018.
8
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.
J Cancer Res Clin Oncol. 2023 Mar;149(3):1273-1283. doi: 10.1007/s00432-022-03966-7. Epub 2022 Apr 19.
9
KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Hum Pathol. 2017 Jul;65:21-30. doi: 10.1016/j.humpath.2017.01.010. Epub 2017 Feb 8.
10
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Adv Clin Exp Med. 2019 Jan;28(1):67-73. doi: 10.17219/acem/76162.
引用本文的文献
1
Effects of PIK3CA Gene Modifications on Radiosensitivity in Colorectal Cancer Cells.
Asian Pac J Cancer Prev. 2025 Jun 1;26(6):1875-1879. doi: 10.31557/APJCP.2025.26.6.1875.
本文引用的文献
1
Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab.
Mol Biol Rep. 2019 Feb;46(1):823-831. doi: 10.1007/s11033-018-4537-5. Epub 2018 Dec 10.
2
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of mutations.
Oncotarget. 2018 Jun 8;9(44):27380-27396. doi: 10.18632/oncotarget.25270.
3
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.
Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2209-2213. doi: 10.22034/APJCP.2017.18.8.2209.
4
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
Tumour Biol. 2016 Jun;37(6):7033-45. doi: 10.1007/s13277-016-4924-2. Epub 2016 Feb 26.
5
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Asian Pac J Cancer Prev. 2014;15(21):9327-33. doi: 10.7314/apjcp.2014.15.21.9327.
6
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.
Br J Cancer. 2013 May 14;108(9):1807-9. doi: 10.1038/bjc.2013.164. Epub 2013 Apr 23.
Zotero 插件